We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+13.44%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$952M
AUM Growth
+$53.7M
(+6%)
Cap. Flow
-$41M
Cap. Flow
% of AUM
-4.31%
Top 10 Holdings %
Top 10 Hldgs %
58.55%
Holding
72
New
9
Increased
10
Reduced
8
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$17.9M |
| 2 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$11.9M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$11.1M |
| 4 |
Incyte
INCY
|
+$7.27M |
| 5 |
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
|
+$6.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
WCRX
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
|
+$16.3M |
| 2 |
Puma Biotechnology
PBYI
|
+$16M |
| 3 |
ONXX
ONYX PHARMACEUTICALS INC
ONXX
|
+$15.5M |
| 4 |
Merck
MRK
|
+$14.1M |
| 5 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$9.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.08% |
| 2 | Financials | 1.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$163B
| $113M | 11.87% |
1,504,712
| – | – |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $86.2M | 9.05% |
1,020,092
| – | – |
|
3
Regeneron Pharmaceuticals
REGN
$77.4B
| $71.8M | 7.53% |
260,699
| – | – |
|
4
Biogen
BIIB
$30.7B
| $53.7M | 5.64% |
191,983
| – | – |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
| $49.4M | 5.19% |
371,329
| – | – |
|
6
Amgen
AMGN
$209B
| $47M | 4.94% |
412,143
| – | – |
|
7
Vertex Pharmaceuticals
VRTX
$122B
| $37.1M | 3.9% |
499,764
| – | – |
|
|
AGN
8
DELISTED
Allergan plc
AGN
| $34.6M | 3.63% |
205,707
+114,207
| +125% | +$17.9M |
|
9
Perrigo
PRGO
$1.43B
| $33.9M | 3.56% |
221,124
+18,517
| +9% | +$2.67M |
|
|
10
iShares Biotechnology ETF
IBB
$9.52B
| $30.9M | 3.24% |
408,318
+156,498
| +62% | +$11.1M |
|
|
11
Incyte
INCY
$24.9B
| $29.8M | 3.13% |
588,300
+167,000
| +40% | +$7.27M |
|
|
AKRX
12
DELISTED
Akorn Inc
AKRX
| $23M | 2.42% |
935,758
| – | – |
|
|
SHPG
13
DELISTED
Shire pic
SHPG
| $21.8M | 2.29% |
154,153
| – | – |
|
14
Viatris
VTRS
$20.7B
| $21.2M | 2.22% |
488,209
| – | – |
|
|
15
Puma Biotechnology
PBYI
$402M
| $19.2M | 2.02% |
185,820
-272,996
| -60% | -$16M |
|
|
AGN
16
DELISTED
Allergan Inc
AGN
| $18.5M | 1.94% |
166,577
| – | – |
|
17
BioMarin Pharmaceuticals
BMRN
$11.7B
| $18.1M | 1.91% |
258,241
+76,371
| +42% | +$5.19M |
|
|
AET
18
DELISTED
Aetna Inc
AET
| $16.9M | 1.78% |
246,841
| – | – |
|
|
CBST
19
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $15.6M | 1.64% |
226,772
| – | – |
|
|
ALR
20
DELISTED
Alere Inc
ALR
| $13.4M | 1.4% |
369,553
| – | – |
|
21
Teva Pharmaceuticals
TEVA
$41.2B
| $12.5M | 1.31% |
311,476
-43,000
| -12% | -$1.69M |
|
22
Verastem
VSTM
$536M
| $11.6M | 1.22% |
84,902
+11,159
| +15% | +$1.47M |
|
23
Illumina
ILMN
$31B
| $11.5M | 1.21% |
106,749
| – | – |
|
|
PCYC
24
DELISTED
PHARMACYCLICS INC
PCYC
| $10.4M | 1.09% |
+98,000
| New | +$11.9M |
|
|
HOLX
25
DELISTED
Hologic
HOLX
| $9.94M | 1.04% |
444,687
-148,228
| -25% | -$3.27M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q4 2013 Portfolio in Review
As of Q4 2013, Tekla Capital Management held 72 positions worth $952M, up 6% from $899M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Tekla Capital Management withdrew a net $41M in Q4 2013, closing 15 positions and reducing 8 holdings. Its most notable exit was WARNER CHILCOTT PLC ORD SHS CL A (IRL), an estimated $16.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier, followed by Financials.
Against the trend, Tekla Capital Management opened a new position in PHARMACYCLICS INC worth $10.4M.
- Tekla Capital Management's largest Q4 2013 buy was PHARMACYCLICS INC: 98,000 shares worth $10.4M.
- Tekla Capital Management added most to Allergan plc in Q4 2013, an estimated $17.9M increase.
- Tekla Capital Management's biggest Q4 2013 reduction was Puma Biotechnology, cutting an estimated $16M.
- Tekla Capital Management fully exited WARNER CHILCOTT PLC ORD SHS CL A (IRL) in Q4 2013, selling an estimated $16.3M.
- Tekla Capital Management's ten largest holdings make up 59% of its $952M portfolio in Q4 2013.
- Tekla Capital Management opened 9 new positions and closed 15 in Q4 2013.
- Tekla Capital Management's portfolio value rose 6% quarter-over-quarter to $952M.
Based on Tekla Capital Management's 13F filing for Q4 2013, filed 28 Jan 2014.